January 9, 2025 04:05 PM EST

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

Kyle LaHucik

Senior Reporter

Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project that’s working with Gilead’s Kite …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint

Versant unveils Light Horse with $62M and a partnership with Novartis

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Bayer says elinzanetant quelled hot flashes in women undergoing cancer treatment

Cell therapy startup A2 Biotherapeutics nets $80M Series C

Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux

Senior Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux